Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.0900 |
| Open | 0.0850 |
| Bid | 0.0850 x N/A |
| Ask | 0.0900 x N/A |
| Day's Range | 0.0850 - 0.0900 |
| 52 Week Range | 0.0050 - 0.1400 |
| Volume | |
| Avg. Volume | 78,822 |
| Market Cap | 6.308M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Aug 27, 2024 - Sept 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company dated May 29, 2023 (the “Indenture”), certain holders (each, a “Debentureholder”) of 12.0 per cent unsecured convertible debentures of the Company (the “Debentures”) have elected to receive common sha
- GlobeNewswire
Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement
All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the undertaking of a non-brokered Private Placement (the “Offering”) for gross proceeds of up to $1.5 million at a purchase price of $0.10 per Unit. This includes l
GlobeNewswireRakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research
Expanded Activities Position Rakovina Therapeutics to Capitalize on AI Partnerships with The University of British Columbia and Pharma Inventor Inc.VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its re
